Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely

This article was originally published in The Pink Sheet Daily

Executive Summary

Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Advertisement

Related Content

Sanofi Loses Another Lovenox Round
Sanofi Loses Another Lovenox Round
Sanofi Vaccine Sales Jump 50 Percent In Q3
Sanofi Vaccine Sales Jump 50 Percent In Q3
Lovenox Clears FDA For STEMI After Priority Review
Momenta Pharmaceuticals CEO Craig Wheeler: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Lovenox’ Days In Court
Sanofi Lovenox Patent To Return To Court
Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics
Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics

Topics

Advertisement
UsernamePublicRestriction

Register

PS065724

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel